Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

459
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
459
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Introduction to Hemostasis01:05

Introduction to Hemostasis

16.1K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
16.1K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

15.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
15.1K
Coagulation01:09

Coagulation

11.9K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
11.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathogen-reduced Red Cells in Cardiac Surgery: Reply.

Anesthesiology·2026
Same author

Amustaline/glutathione pathogen-reduced red cell hemoglobin utilization in complex cardiac surgery: A post hoc analysis of the phase 3 ReCePI trial.

Transfusion·2025
Same author

Transfusion of Amustaline/Glutathione Pathogen-reduced Red Blood Cells in Cardiac Surgery: A Randomized Phase 3 Clinical Trial.

Anesthesiology·2025
Same author

Human red blood cell ATP content and export under hypoxic and/or isocapnic storage conditions.

Frontiers in physiology·2025
Same author

Perioperative Bleeding Risk in Lung Transplantation After Previous Cardiothoracic Surgery.

Clinical transplantation·2025
Same author

Impact of Point-of-care Allogeneic Red Blood Cell Washing on Markers of Transfusion-related Respiratory Complications: A Phase II Randomized Clinical Trial.

Anesthesiology·2025

Related Experiment Video

Updated: Mar 24, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

68

Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting.

Kamrouz Ghadimi1, Jerrold H Levy, Ian J Welsby

  • 1From the Divisions of Cardiothoracic Anesthesiology and Critical Care Medicine, Duke University Medical Center, Durham, North Carolina.

Anesthesia and Analgesia
|March 17, 2016
PubMed
Summary
This summary is machine-generated.

Prothrombin complex concentrates (PCCs) rapidly restore clotting factors for bleeding but carry thromboembolic risks. Tailoring PCC dose and considering other coagulopathies are crucial for safe perioperative use.

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

1.2K
Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial
08:14

Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial

Published on: September 29, 2015

13.6K

Related Experiment Videos

Last Updated: Mar 24, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

68
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

1.2K
Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial
08:14

Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial

Published on: September 29, 2015

13.6K

Area of Science:

  • Hematology
  • Anesthesiology
  • Critical Care Medicine

Background:

  • Prothrombin complex concentrates (PCCs) contain vitamin K-dependent clotting factors (II, VII, IX, X).
  • PCCs are FDA-approved for reversing vitamin K antagonists but are increasingly used off-label for surgical bleeding.
  • Limited prospective data exist on PCC safety and efficacy for perioperative bleeding.

Purpose of the Study:

  • To review the use of PCCs in perioperative settings.
  • To discuss balancing hemostatic benefits against thromboembolic risks.
  • To highlight the need for further research on safe and effective PCC administration.

Main Methods:

  • Literature review of PCC use in perioperative bleeding.
  • Analysis of factors influencing thromboembolic risk.
  • Discussion of individualized treatment strategies.

Main Results:

  • PCCs can rapidly restore coagulation but pose a thromboembolic risk dependent on dose and patient factors.
  • Off-label use of PCCs for surgical bleeding is growing, necessitating careful management.
  • Perioperative PCC administration may be individualized using lab tests to balance risks and benefits.

Conclusions:

  • Individualized PCC dosing and consideration of other coagulopathies are key in perioperative bleeding.
  • Thromboembolic risk persists post-hemostasis due to factor half-lives.
  • Further studies are needed to optimize safe and effective PCC use in perioperative care.